Dicathais orbita is a large Australian marine gastropod known to produce bioactive compounds with anticancer properties. In this research, we used bioassay guided fractionation from the egg mass extract of D. orbita using flash column chromatography and identified fractions containing tyrindoleninone and 6-bromoisatin as the most active against colon cancer cells HT29 and Caco-2. Liquid chromatography coupled with mass spectrometry (LCMS) and 1H NMR were used to characterize the purity and chemical composition of the isolated compounds. An MTT assay was used to determine effects on cell viability. Necrosis and apoptosis induction using caspase/LDH assay and flow cytometry (PI/Annexin-V) and cell cycle analysis were also investigated. Our results show that semi-purified 6-bromoisatin had the highest anti-cancer activity by inhibiting cell viability (IC 50 = ~100 μM) and increasing caspase 3/7 activity in both of the cell lines at low concentration. The fraction containing 6-bromoisatin induced 77.6% apoptosis and arrested 25.7% of the cells in G2/M phase of cell cycle in HT29 cells. Tyrindoleninone was less potent but significantly decreased the viability of HT29 cells at IC 50 = 390 μM and induced apoptosis at 195 μM by increasing caspase 3/7 activity in these cells. This research will facilitate the development of these molluscan natural products as novel complementary medicines for colorectal cancer.
References
[1]
Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90, doi:10.3322/caac.20107.
[2]
Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893–2917, doi:10.1002/ijc.25516.
[3]
Carnesecchi, S.; Langley, K.; Exinger, F.; Gosse, F.; Raul, F. Geraniol, a component of plant essential oils, sensitizes human colonic cancer cells to 5-fluorouracil treatment. J. Pharmacol. Exp. Ther. 2002, 301, 625–630, doi:10.1124/jpet.301.2.625.
[4]
Line-Edwige, M. Antiproliferative effect of alcoholic extracts of some Gabonese medicinal plants on human colonic cancer cells. Afr. J. Tradit. Complement. Altern. Med. 2009, 6, 112–117.
[5]
Harvey, A.L. Natural products as a screening resource. Curr. Opin. Chem. Biol. 2007, 11, 480–484, doi:10.1016/j.cbpa.2007.08.012.
[6]
Harvey, A. Strategies for discovering drugs from previously unexplored natural products. Drug Discov. Today 2000, 5, 294–300, doi:10.1016/S1359-6446(00)01511-7.
[7]
Esmaeelian, B.; Kamrani, Y.Y.; Amoozegar, M.A.; Rahmani, S.; Rahimi, M.; Amanlou, M. Anti-cariogenic properties of malvidin-3,5-diglucoside isolated from Alcea longipedicellata against oral bacteria. Int. J. Pharmacol. 2007, 3, 468–474, doi:10.3923/ijp.2007.468.474.
[8]
Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461–477, doi:10.1021/np068054v.
[9]
Rajamanickam, S.; Agarwal, R. Natural products and colon cancer: Current status and future prospects. Drug Dev. Res. 2008, 69, 460–471, doi:10.1002/ddr.20276.
[10]
Manson, M.M.; Farmer, P.B.; Gescher, A.; Steward, W.P. Innovative agents in cancer prevention. Recent Results Cancer Res. 2005, 166, 257–275, doi:10.1007/3-540-26980-0_17.
Benkendorff, K. Molluscan biological and chemical diversity: Secondary metabolites and medicinal resources produced by marine molluscs. Biol. Rev. 2010, 85, 757–775.
Sato, M.; Sagawa, M.; Nakazato, T.; Ikeda, Y.; Kizaki, M. A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int. J. Oncol. 2007, 30, 1453–1459.
[16]
Jiang, C.; Wang, M.; Liu, J.; Gan, D.; Zeng, X. Extraction, preliminary characterization, antioxidant and anticancer activities in vitro of polysaccharides from Cyclina sinensis. Carbohydr. Polym. 2011, 84, 851–857, doi:10.1016/j.carbpol.2010.11.027.
[17]
Baker, J. Tyrian purple: An ancient dye, a modern problem. Endeavour 1974, 33, 11–17, doi:10.1016/0160-9327(74)90003-9.
[18]
Benkendorff, K.; Bremner, J.B.; Davis, A.R. Tyrian purple precursors in the egg masses of the Australian muricid, Dicathais orbita: A possible defensive role. J. Chem. Ecol. 2000, 26, 1037–1050, doi:10.1023/A:1005441116095.
[19]
Cooksey, C.J. Tyrian purple: 6,6′-dibromoindigo and related compounds. Molecules 2001, 6, 736–769, doi:10.3390/60900736.
[20]
Baker, J.T.; Duke, C.C. Isolation of choline and choline ester salts of tyrindoxyl sulphate from the marine mollusks Dicathais orbita and Mancinella keineri. Tetrahedron Lett. 1976, 1233–1234, doi:10.1016/S0040-4039(00)78026-9.
[21]
Westley, C.B.; Vine, K.L.; Benkendorff, K. A Proposed Functional Role for Indole Derivatives in Reproduction and Defense of the Muricidae (Neogastropoda: Mollusca). In Indirubin, the Red Shade of Indigo; Meijer, L., Guyard, N., Skaltsounis, L., Eisenbrand, G., Eds.; Life in Progress Editions: Roscoff, France, 2006; pp. 31–44.
[22]
Westley, C.B.; McIver, C.M.; Abbott, C.A.; Le Leu, R.K.; Benkendorff, K. Enhanced acute apoptotic response to azoxymethane-induced DNA damage in the rodent colonic epithelium by Tyrian purple precursors: A potential colorectal cancer chemopreventative. Cancer Biol. Ther. 2010, 9, 371–379, doi:10.4161/cbt.9.5.10887.
[23]
Cooksey, C.J. Marine Indirubins. In Indirubin, the Red Shade of Indigo; Meijer, L., Guyard, N., Skaltsounis, L., Eisenbrand, G., Eds.; Life in Progress Editions: Roscoff, France, 2006; pp. 23–30.
[24]
Westley, C.; Benkendorff, K. Sex-specific Tyrian purple genesis: Precursor and pigment distribution in the reproductive system of the marine mollusc, Dicathais orbita. J. Chem. Ecol. 2008, 34, 44–56, doi:10.1007/s10886-007-9402-2.
[25]
Benkendorff, K. The Australian Muricidae Dicathais orbita: A model species for marine natural product research. Mar. Drugs 2013, 11, 1370–1398, doi:10.3390/md11041370.
[26]
Benkendorff, K.; McIver, C.M.; Abbott, C.A. Bioactivity of the Murex homeopathic remedy and of extracts from an Australian muricid mollusc against human cancer cells. Evid. Based Complement. Altern. Med. 2011, 2011, 879585.
[27]
Edwards, V.; Benkendorff, K.; Young, F. Marine compounds selectively induce apoptosis in female reproductive cancer cells but not in primary-derived human reproductive granulosa cells. Mar. Drugs 2012, 10, 64–83, doi:10.3390/md10010064.
[28]
Vine, K.L.; Locke, J.M.; Ranson, M.; Benkendorff, K.; Pyne, S.G.; Bremner, J.B. In vitro cytotoxicity evaluation of some substituted isatin derivatives. Bioorg. Med. Chem. 2007, 15, 931–938, doi:10.1016/j.bmc.2006.10.035.
[29]
Meijer, L.; Skaltsounis, A.L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X.P.; Vonica, C.A.; Brivanlou, A.; Dajani, R. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 2003, 10, 1255–1266, doi:10.1016/j.chembiol.2003.11.010.
[30]
Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J.A.; Snyder, G.L.; Greengard, P.; Biernat, J.; Wu, Y.Z.; Mandelkow, E.M. Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. J. Biol. Chem. 2001, 276, 251–260.
[31]
Noble, W.J.; Cocks, R.R.; Harris, J.O.; Benkendorff, K. Application of anaesthetics for sex identification and bioactive compound recovery from wild Dicathais orbita. J. Exp. Mar. Biol. Ecol. 2009, 380, 53–60, doi:10.1016/j.jembe.2009.09.006.
[32]
Benkendorff, K. Aquaculture and the Production of Pharmaceuticals and Nutraceuticals; Woodhead Publishing: Cambridge, UK, 2009; pp. 866–891.
[33]
Westley, C.B.; Benkendorff, K.; McIver, C.M.; Le Leu, R.K.; Abbott, C.A. Gastrointestinal and hepatotoxicity assessment of an anticancer extract from muricid molluscs. Evid. Based Complement. Altern. Med. 2013, 2013, 837370.
[34]
Baker, J.; Duke, C. Chemistry of the indoleninones. II. Isolation from the hypobranchial glands of marine molluscs of 6-Bromo-2,2-dimethylthioindolin-3-one and 6-Bromo-2-methylthioindoleninone as alternative precursors to Tyrian purple. Aust. J. Chem. 1973, 26, 2153–2157, doi:10.1071/CH9732153.
[35]
Jin, Z.; El-Deiry, W.S. Review overview of cell death signaling pathways. Cancer Biol. Ther. 2005, 4, 139–163, doi:10.4161/cbt.4.2.1508.
[36]
Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516, doi:10.1080/01926230701320337.
[37]
Vine, K.L. An Investigation into the Cytotoxic Properties of Isatin-Derived Compounds: Potential for Use in Targeted Cancer Therapy. Ph.D. Thesis, University of Wollongong, Wollongong, Australia, 14 September 2007.
[38]
Rochat, B. Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. Curr. Cancer Drug Targets 2009, 9, 652–674, doi:10.2174/156800909789056999.
[39]
Vine, K.; Matesic, L.; Locke, J.; Ranson, M.; Skropeta, D. Cytotoxic and anticancer activities of isatin and its derivatives: A comprehensive review from 2000–2008. Anticancer Agents Med. Chem. 2009, 9, 397–414, doi:10.2174/1871520610909040397.
[40]
Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267, 1456–1462, doi:10.1126/science.7878464.
[41]
Gamet-Payrastre, L.; Li, P.; Lumeau, S.; Cassar, G.; Dupont, M.-A.; Chevolleau, S.; Gasc, N.; Tulliez, J.; Tercé, F. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000, 60, 1426–1433.
[42]
Nguyen, J.T.; Wells, J.A. Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 7533–7538, doi:10.1073/pnas.1031631100.
[43]
Riss, T.L.; Moravec, R.A. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev. Technol. 2004, 2, 51–62, doi:10.1089/154065804322966315.
[44]
Pozhilenkova, E.; Salmina, A.; Yamanova, M.; Ruksha, T.; Mikhutkina, S.; Trufanova, L. Disorders of folliculogenesis are associated with abnormal expression of peripheral benzodiazepine receptors in granulosa cells. Bull. Exp. Biol. Med. 2008, 145, 29–32, doi:10.1007/s10517-008-0017-6.
[45]
Vine, K.L.; Locke, J.M.; Ranson, M.; Pyne, S.G.; Bremner, J.B. An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins. J. Med. Chem. 2007, 50, 5109–5117, doi:10.1021/jm0704189.
[46]
Weng, J.-R.; Tsai, C.-H.; Kulp, S.K.; Wang, D.; Lin, C.-H.; Yang, H.-C.; Ma, Y.; Sargeant, A.; Chiu, C.-F.; Tsai, M.-H. A potent indole-3-carbinol–derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Res. 2007, 67, 7815–7824, doi:10.1158/0008-5472.CAN-07-0794.
[47]
Nicholson, D. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999, 6, 1028–1042.
[48]
Cane, A.; Tournaire, M.-C.; Barritault, D.; Crumeyrolle-Arias, M. The endogenous oxindoles 5-hydroxyoxindole and isatin are antiproliferative and proapoptotic. Biochem. Biophys. Res. Commun. 2000, 276, 379–384, doi:10.1006/bbrc.2000.3477.
[49]
Steinmetz, R.; Wagoner, H.A.; Zeng, P.; Hammond, J.R.; Hannon, T.S.; Meyers, J.L.; Pescovitz, O.H. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol. Endocrinol. 2004, 18, 2570–2582, doi:10.1210/me.2004-0082.
[50]
Georgakis, G.V.; Li, Y.; Rassidakis, G.Z.; Martinez-Valdez, H.; Medeiros, L.J.; Younes, A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin’s lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal–regulated kinase, and induces cell cycle arrest and cell death. Clin. Cancer Res. 2006, 12, 584–590, doi:10.1158/1078-0432.CCR-05-1194.
[51]
Zhuang, S.; Schnellmann, R.G. A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 2006, 319, 991–997, doi:10.1124/jpet.106.107367.
[52]
DiPaola, R.S. To arrest or not to G2-M cell-cycle arrest commentary re: AK Tyagi et al., silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin. Cancer. Res. 2002, 8, 3311–3314.
Damiens, E.; Baratte, B.; Marie, D.; Eisenbrand, G.; Meijer, L. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: Induction of endoreplication following prophase arrest. Oncogene 2001, 20, 3786–3797, doi:10.1038/sj.onc.1204503.
[55]
Davis, S.T.; Benson, B.G.; Bramson, H.N.; Chapman, D.E.; Dickerson, S.H.; Dold, K.M.; Eberwein, D.J.; Edelstein, M.; Frye, S.V.; Gampe, R.T., Jr. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001, 291, 134–137, doi:10.1126/science.291.5501.134.
[56]
Lane, M.E.; Yu, B.; Rice, A.; Lipson, K.E.; Liang, C.; Sun, L.; Tang, C.; McMahon, G.; Pestell, R.G.; Wadler, S. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001, 61, 6170–6177.
[57]
Hoessel, R.; Leclerc, S.; Endicott, J.A.; Nobel, M.E.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 60–67, doi:10.1038/9035.
[58]
Marko, D.; Sch？tzle, S.; Friedel, A.; Genzlinger, A.; Zankl, H.; Meijer, L.; Eisenbrand, G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 2001, 84, 283–289, doi:10.1054/bjoc.2000.1546.
[59]
Jautelat, R.; Brumby, T.; Sch？fer, M.; Briem, H.; Eisenbrand, G.; Schwahn, S.; Krüger, M.; Lücking, U.; Prien, O.; Siemeister, G. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. ChemBioChem 2005, 6, 531–540, doi:10.1002/cbic.200400108.
[60]
Eisenbrand, G.; Hippe, F.; Jakobs, S.; Muehlbeyer, S. Molecular mechanisms of indirubin and its derivatives: Novel anticancer molecules with their origin in traditional Chinese phytomedicine. J. Cancer Res. Clin. Oncol. 2004, 130, 627–635, doi:10.1007/s00432-004-0579-2.
Adachi, J.; Mori, Y.; Matsui, S.; Takigami, H.; Fujino, J.; Kitagawa, H.; Miller Iii, C.A.; Kato, T.; Saeki, K.; Matsuda, T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 2001, 276, 31475–31478, doi:10.1074/jbc.C100238200.
[63]
Spink, B.C.; Hussain, M.M.; Katz, B.H.; Eisele, L.; Spink, D.C. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin. Biochem. Pharmacol. 2003, 66, 2313–2321, doi:10.1016/j.bcp.2003.08.019.
[64]
Andreani, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Garaliene, V.; Welsh, W.; Arora, S.; Farruggia, G. Antitumor activity of new substituted 3-(5-Imidazo [2,1-b] thiazolylmethylene)-2-indolinones and study of their effect on the cell cycle 1. J. Med. Chem. 2005, 48, 5604–5607, doi:10.1021/jm050353e.
[65]
Chen, Z.; Merta, P.J.; Lin, N.-H.; Tahir, S.K.; Kovar, P.; Sham, H.L.; Zhang, H. A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth. Mol. Cancer Ther. 2005, 4, 562–568, doi:10.1158/1535-7163.MCT-04-0229.
[66]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63, doi:10.1016/0022-1759(83)90303-4.
[67]
Young, F.M.; Phungtamdet, W.; Sanderson, B.J. Modification of MTT assay conditions to examine the cytotoxic effects of amitraz on the human lymphoblastoid cell line, WIL2NS. Toxicol. In Vitro 2005, 19, 1051–1059, doi:10.1016/j.tiv.2005.05.001.
